Multiple Sclerosis (MS †) is a chronic autoimmune disorder affecting the Central Nervous System (CNS) through inflammation, demyelination and neurodegeneration. Sphingosine-1-phosphate receptor (S1PR1) modulators have been approved for the management of MS. Phosphorylated fingolimod mimics endogenous sphingosine-1-phosphate (S1P), a bioactive lipid that regulates remyelination and cell injury. Amiselimod was developed as a successor of fingolimod, with more specificity for S1PR1, and showed promising results until phase 2 clinical trials. This study utilized the fingolimod and amiselimod scaffolds, together with their critical binding interactions for the S1PR1 Ligand Binding Pocket, as templates for the in silico de novo design of high efficiency binding Lipinski rule-compliant molecules. A rigorous selection process identified two molecules, Molecules 003 and 019, deriving from fingolimod and amiselimod, respectively, which were deemed most suitable for further optimization.
INTRODUCTION
Multiple Sclerosis (MS) is a chronic disorder affecting the Central Nervous System (CNS) through inflammation, demyelination, and neurodegeneration. Sphingosine-1-phosphate receptor (S1PR 1 ) modulators have been approved for the management of MS. Phosphorylated fingolimod mimics endogenous sphingosine-1-phosphate (S1P), a bioactive lipid that regulates remyelination [1] . Structure-activity relationship (SAR) data regarding fingolimod are indicative of three key structural features. These are the aminodiol (hydroxymethyl) polar head group, which undergoes phosphorylation by Sphingosine Kinase 2, the 1,4-disubstituted phenyl ring, which rigidifies the conformation, and the lipophilic octylphenyl tail, which interacts with hydrophobic ligand binding pocket of the Sphingosine-1-Phosphate receptors [2] . Amiselimod [3] , whose clinical trials as fingolimod's successor were discontinued while this study was being carried out, has greater hydrogen bond acceptor capabilities relative to fingolimod due to the trifluoromethyl substituent on its phenyl ring.
The immunomodulatory action of fingolimod is achieved through a number of metabolic pathways. Firstly, the sphingosine kinase metabolizes the pro-drug to the active metabolite fingolimod-phosphate. Fingolimod-phosphate binds at minimal nanomolar concentrations to S1PR 1 located on lymphocytes and, due to its lipophilic character, readily crosses the blood-brain barrier (BBB) to bind to S1PR 1 located on neural cells in the CNS. By acting as a functional antagonist of S1PR on lymphocytes, fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, redistributing lymphocytes in the process. Fingolimod has an oral bioavailability of 93 percent after absorption, with steady-state blood concentrations taking 1 to 2 months with a daily dose. It is highly protein-bound, with a higher distribution in red blood cells. Biotransformation to the active S-fingolimod-phosphate occurs whereby elimination takes place primarily by CYP4F2 catalysis and is eventually excreted mainly through urine [4] . This study was a first step in the design of more selective S1PR 1 modulators, using the fingolimod and [19] .
amiselimod scaffolds and their critical binding interactions with the S1PR 1 Ligand Binding Pockets (LBP) as templates ( Figure 1) . A de novo approach was initially adopted to design and optimize novel ligands for the S1PR 1. In the second part of the study, potential novel S1PR1 modulators were sought using a Virtual Screening (VS) approach. The identification of novel S1PR 1 modulators could potentially yield better molecules with neuro-protective properties beneficial in MS, without the risk of the fingolimod-associated bradycardia [5] .
MATERIALS AND METHODS
In the de novo design process, X-ray crystallographic deposition 3V2Y describing the holo selective antagonist mimic, ML056, bound to S1PR 1 , was selected as a template [6] . Molecular modeling was carried out in Sybyl-X [7] . The apo S1PR 1 _LBP was mapped using the POCK-ET module of LigBuilder v1.2 [8] . This delineated the 3D-space within which novel molecular growth could be sustained. SAR studies from the literature [2] and the generation of 2D topology maps using Poseview [9] guided the modeling of four (labeled A-D in Figure 2 ) and three seed structures (labeled A-C in Figure 3 ) from the fingolimod and amiselimod conformers identified as optimally binding through conformational analysis, respectively. These were strategically planted into the S1PR_LBP, and novel moieties were computationally attached using the GROW module of LigBuilder v1.2 [8] at loci considered non-critical for binding. The analysis of drug-likeness of each resultant ligand was assessed based on the dual concepts of Lipinski rule-of-five and in silico-calculated Ligand Binding Affinity (LBA) (pKd) using the scoring function, X-Score v1.3 [10] . pKd may be defined as the sum that describes the overall stability of the interactions that occur in a ligand-receptor complex. Drug-likeness analysis based on the Lipinski rule-of-five meant that compliant molecules satisfied the criterion of having a molecular weight of not more than 500, a LogP not greater than five, hydrogen bond donors amounting to five or less, and hydrogen bond acceptors amounting to 10 or less [11] . The notion of having Lipisnki rule-compliant molecules relates to the molecules being able to diffuse passively through the BBB.
In the VS approach, the fingolimod and amiselimod conformers identified as optimally binding through conformational analysis, together with the highest ranking ligands identified through the de novo approach, were uploaded to the online database ViCi [12] hosted by the University of Hamburg, in order to identify ligands of similar Three-Dimensional structural orientation and outer electronic configuration. The obtained hits were fil- Table 1 . The properties of the best generated ligands of the de novo drug design that are Lipinski compliant with highest binding score, generated from LigBuilder v1.2 [8] . [19] .
RESULTS
In the de novo approach, planting of the modeled seed fragments into the S1PR 1 -LBP and use of the GROW algorithm of LigBuilder v1.2 [8] resulted in the generation of a total of 630 and 149 Lipinski rule-compliant fingolimod-and amiselimod-derived molecules, respectively. These were grouped into 23 (fingolimod-derived) and 12 (amiselimod-derived) pharmacophorically similar families ( Figure 4 ).
The LBA (pK d ) for the de novo-generated molecules tered for Lipinski compliance using Mona [13] . A protomol ( Figure 5A ) describing the total area available for ligand binding at the core of the S1PR 1 was generated in Sybyl-X [7] and used as a docking platform for the Lipinski rule-compliant molecules deriving from the online molecular database search. The ligands were re-filtered now based on their total affinity scores, and adapted Lipinski rule compliance in which LogP ranges between 3.15 and 4.96 were considered as predictors of CNS penetration [14] . Table 2 . The properties of the best generated ligands of the in silico drug design that are Lipinski compliant with highest total score, generated from Sybyl-X [7] and predicted binding energy and pKd from X-Score v1.3 [10] . The de novo-designed molecules deemed optimal were Molecule 003 ( Figure 1B ) generated from seed D of fingolimod ( Figure 1A) , having a pKd value of 7.85, a LogP value of 4.93 and a molecular weight of 421 daltons; and Molecule 019 ( Figure 1D ) generated from seed C of amiselimod ( Figure 1C) , having a pKd value of 7.17, a LogP value of 4.47 and a molecular weight of 316 dalfor the fingolimod-derived molecules ranged from 5.17 and 7.85, with molecular weight ranging between 313 and 481 daltons. The range for logP was between 3.15 and 4.99. The pK d for the de novo-generated molecules derived from amiselimod ranged from 5.11 and 7.17, while the molecular weight ranged between 301 and 455 daltons. LogP ranged between 3.04 and 4.96. 
DISCUSSION
The POCKET algorithm of LigBuilder® v1.2 [8] was used to generate fingolimod-and amiselimod-bound LBP maps of the S1PR 1 ( Figure 5B ). These maps were color-coded according to polarity highlighting different loci rich in hydrogen bond donors, acceptors, and hydrophobic groups, respectively. Visualisation of the fingolimod-and amiselimod-circumscribed LBPs, revealed very similar LBP maps. It was, however, interesting to note a different binding modality between amiselimod and fingolimod, with fingolimod exhibiting a somewhat curved binding modality and amiselimod assuming a 90-degree orientation within the S1PR 1 _LBP.
The optimal fingolimod-and amiselimod-derived molecules were selected based on the combined notions of high LBA (pK d ) and low binding energy (kcalmol -1 ). Figure 7 and Figure 8 for fingolimod and amiselimod, respectively.
In the VS approach, a protomol was generated (Figure 5A ). Predictably, this had a larger surface area and volume as compared to the LBP maps generated for the fingolimod-and amiselimod-bound S1PR 1 , respectively. A protomol is a map of energetically unstable amino acids at the core of a receptor and is not delineated by a resident ligand, consequently providing more interaction sites than ligand circumscribed maps.
The hits obtained through VS were docked into the protomol. The three highest ranking molecules in terms of total scores were as shown in Table 2 : Fingolimod-de- was identified through the de novo approach is markedly different from those of fingolimod and amiselimod. The most striking differences are at the level of the ring, which has been opened in Molecule 003, and also at the level of the side chain, which, in the case of Molecule 003, now branches out to fill the available space more completely than do the side chains of fingolimod and amiselimod.
The clinical consequences of these novel interactions must be investigated, particularly from an adverse effect perspective.
As evidenced by Table 3 , Molecule 003 has the highest LBA (pKd) of 7.04 followed by Molecule 019 (LBA (pKd)=) and by amiselimod and fingolimod (LBA (pKd)= 5.83 and 5.69 respectively). LogP was highest for the new molecules, with Molecule 003 having a LogP of 4.20 when compared to fingolimod, whose LogP was 3.27. Molecule 019 had a LogP value of 3.96, whilst amiselimod had a LogP value of 2.95. The Topological Polar Surface Area (TPSA) is highest for Molecule 003, 88.3 and amiselimod, 77.3. Lipophilic Ligand Efficiency (LLE) is moderate with both fingolimod and Molecule 003, whereas poor with amiselimod and Molecule 019. Molecule 019 is predicted to penetrate the blood-brain barrier.
The docking process concerns the prediction of ligand conformation and orientation within a targeted binding site [15] . The protomol generated in the context of the VS approach was innovative and different from the LBP maps generated using the POCKET module of LigBuilder® v1.2 [8] . This indicated the existence of additional binding sites, which could potentially be utilized in an
The selection of lower-energy conformations was based on the premise that molecular stability is conferred by the positive ratio between intramolecular attractive to repulsive forces, and that the surplus of attractive forces will lower the overall potential energy of the molecule.
Optimal molecule 003, Figure 1B , generated from 
CONCLUSION
This study is a report of an initial in silico study that, given the adverse effect profile of fingolimod, seeks to identify structurally diverse lead molecules with clinical efficacy that is similar to or better than that of fingolimod, but that do not elicit the documented fingolimod-associated bradycardia. This study consequently proposes that this structural diversity be explored in the quest to identify clinically useful molecules with a more acceptable side effect profile.
attempt to identify novel suitable ligand interactions that could potentially favor efficacy and reduce side effects. Alternative site binding could also lead to hitherto unrecognized receptor conformational changes, potentially also contributing to partial or full modulation of the target receptor.
This in silico study is valuable in having identified two molecules whose high efficiency binding and associated physicochemical parameters support the hypothesis of high selectivity and oral bioavailability. This hypothesis requires molecular dynamics, in vitro, and in vivo validation.
In this context, we are publishing the results of a static in silico study. While conformational analysis, which was used to identify the optimal conformations of fingolimod and amiselimod within the S1PR 1 _LBP, allowed single bond and ring rotations within a static binding pocket, it is envisaged that the next step in this study will be the setting up of a comparative Molecular Dynamics simulation study, in which the most important motions of fingolimod and amiselimod and the S1PR 1 will be compared statistically with those of molecules 003 and 019 using Principal Component Analysis (PCA). This will allow a better understanding of the nature of the interactions of molecules 003 and 019 with the S1PR 1 , and will allow for enhanced atomic explanation of in vitro assay results.
Optimization of S1PR 1 modulators is still required in order to minimize adverse effects. Selectivity remains key in reducing adverse effects, with the exact cause of bradycardia remaining unclear but being apparently S1PR subtype 1 related. Other agents have exhibited other adverse effects in the course of undergoing clinical trials. Ponesimod (selective S1PR 1 ) was associated (2 percent of participants) with bradycardia, and with 1.2 percent and 0.9 percent of participants experiencing first and second degree heart block, respectively. Other reported effects were dyspnea and peripheral edema related to respiratory effects, together with altered alanine aminotransferase (ALT). Participants taking Siponimod (selective for S1PR 1 and S1PR 5 ) experienced second degree block and bradycardia, with one case of mortality in a patient with a history of coronary artery disease being reported. A study on Siponimod (BAF312) carried out by Gergely et al. proposes that bradycardia may be species-dependent. Ozanimod (selective for S1PR 1 ) exhibited serious adverse effects, specifically optic neuritis, uterine cervical squamous metaplasia, and somatoform autonomic dysfunction [16] . Amiselimod (selective for S1PR 1 ) showed promising results, but was discontinued after a successful phase two trial. Its withdrawal was not adverse effect-related, but seems to have been related to alternative fund allocation in what was termed a competitive regulatory landscape [16] .
